Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte flags 2022 revenue growth, sets new guidance

Tue, 07th Mar 2023 09:32

(Sharecast News) - Cell engineering technology company MaxCyte said in an update on Tuesday that it was expecting full-year 2022 total revenue of $44.3m, which would represent growth of 31% over 2021.

The AIM-traded firm said its fourth quarter total revenue was expected to total $12.4m, making for year-on-year growth of 22%.

It said its installed base at the end of 2022 was higher than 600 instruments, compared to over 500 instruments at the end of the prior year.

The company's total SPL partnerships of 18 at year-end, including three added in 2022 itself, were described as "instrumental" in driving growth.

In January, MaxCyte announced an additional SPL partnership with Catamaran Bio, which it said would further expand the company's market reach.

MaxCyte laid out its initial 2023 guidance for total revenue growth of between 21% and 26% over 2022, including core revenue growth of 20% to 25%, and SPL programme-related revenue of around $6m.

"We delivered strong growth across the business in 2022, giving us confidence as reflected in our initial 2023 revenue guidance," said president and chief executive officer Doug Doerfler.

"Our diverse and robust partnership portfolio continues to grow with three new partnerships added in 2022, in addition to the signing of a partnership with Vertex Pharmaceuticals following the transfer from CRISPR Therapeutics for the development of its CRISPR/Cas9-based gene-edited therapy.

"We look forward to further expansion of our partnerships based on a strong pipeline and the continued progression of our partners' programs as they move into and through the clinic towards commercialisation."

At 1100 GMT, shares in MaxCyte were flat at 390p.

Reporting by Josh White for Sharecast.com.

More News
30 Jul 2021 20:39

TRADING UPDATES: Cambria Automobiles suitor tables improved offer

TRADING UPDATES: Cambria Automobiles suitor tables improved offer

Read more
30 Jul 2021 12:25

MaxCyte announces pricing of upsized Nasdaq share offering

(Sharecast News) - Cell engineering technology company MaxCyte announced the pricing of its upsized offering of 13,500,000 shares on Nasdaq on Friday, at a price of $13.00 per share.

Read more
26 Jul 2021 20:23

TRADING UPDATES: Attraqt and tinyBuild trade in line in first half

TRADING UPDATES: Attraqt and tinyBuild trade in line in first half

Read more
19 Jul 2021 21:48

IN BRIEF: MaxCyte makes administrative changes ahead of Nasdaq listing

IN BRIEF: MaxCyte makes administrative changes ahead of Nasdaq listing

Read more
29 Jun 2021 15:53

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Jun 2021 19:33

EXECUTIVE CHANGES: Keywords Studies CEO Day retires after 12 years

EXECUTIVE CHANGES: Keywords Studies CEO Day retires after 12 years

Read more
25 May 2021 19:40

TRADING UPDATES: Bank of Cyprus outlook hinges on tourism industry

TRADING UPDATES: Bank of Cyprus outlook hinges on tourism industry

Read more
25 May 2021 11:45

MaxCyte signs strategic partnership with Celularity

(Sharecast News) - Cell-based therapy developer MaxCyte announced the signing of a strategic platform licence with clinical-stage biotechnology company Celularity on Tuesday.

Read more
14 May 2021 14:13

IN BRIEF: MaxCyte prepares for listing in New York

IN BRIEF: MaxCyte prepares for listing in New York

Read more
14 May 2021 09:05

MaxCyte proposes dual listing on Nasdaq

(Sharecast News) - Cell engineering technology company MaxCyte has submitted a draft registration statement with the Securities and Exchange Commission (SEC), it announced on Friday, for a proposed dual-listing and public offering of shares on the Nasdaq market.

Read more
13 May 2021 19:16

IN BRIEF: MaxCyte to consolidate two lines of common stock into one

IN BRIEF: MaxCyte to consolidate two lines of common stock into one

Read more
13 May 2021 11:22

MaxCyte to consolidate two of its lines of shares

(Sharecast News) - Cell engineering company MaxCyte announced the consolidation of two of its lines of common stock into a single unrestricted line of common stock on Thursday.

Read more
20 Apr 2021 12:08

TRADING UPDATES: Zegona profit sinks; Flowtech Fluidpower suffers loss

TRADING UPDATES: Zegona profit sinks; Flowtech Fluidpower suffers loss

Read more
20 Apr 2021 09:22

MaxCyte reports good performance despite Covid challenges

(Sharecast News) - Cell engineering technology company MaxCyte reported a 21% year-on-year improvement in revenues in its final results on Tuesday, to $26.2m (£18.74m), despite the challenges of the Covid-19 pandemic.

Read more
4 Feb 2021 09:41

MaxCyte raises £40m from new and existing investors

(Sharecast News) - Cell engineering and life sciences company MaxCyte has announced a subscription to raise £40m, in a bid to strengthen its balance sheet.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.